Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 1, 2003, Pages 21-43

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

1 O hexadecyloxypropyl cidofovir; Acyclic nucleoside phosphonates; Adefovir; Adefovir dipivoxil; Cidofovir; Tenofovir; Tenofovir disoproxil fumarate

Indexed keywords

ACICLOVIR; ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; CIDOFOVIR; CYCLOSPORIN; EFAVIRENZ; EMTRICITABINE; FOSCARNET; GANCICLOVIR; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENCICLOVIR; PROBENECID; RITUXIMAB; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ACIDOSIS; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COWPOX VIRUS; CYTOMEGALOVIRUS; DNA VIRUS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; EPSTEIN BARR VIRUS; FELINE IMMUNODEFICIENCY VIRUS; GLUCOSURIA; HEMANGIOMA; HEPADNAVIRUS; HEPATITIS B; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HYPOPHOSPHATEMIA; KAPOSI SARCOMA; METABOLIC DISORDER; MOLLUSCIPOXVIRUS; NASOPHARYNX CARCINOMA; NEPHROTOXICITY; NONHUMAN; PROTEINURIA; RETINITIS; RETROVIRUS; RETROVIRUS INFECTION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; SKIN MANIFESTATION; SMALLPOX VIRUS; UTERINE CERVIX CARCINOMA; VACCINIA VIRUS; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

EID: 2342451795     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.1.21     Document Type: Review

References (136)

1. De Clercq E. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5, 149-164 (1995).
2. Field AK, Biron KK. 'The end of innocence' revisited: resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev. 7, 1-13 (1994).
3. De Clercq E. Broad spectrum antiDNA virus and antiretrovirus activity of phosphonylmethoxyalkylpurines and pyrimidines. Biochem, Pharmacol. 42, 963-972 (1991).
4. Cihlar T, Chen MS. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50, 1502-1510 (1996).
5. Balzarini J, Navé J-F, Becker MA, Tatibana M, De Clercq E. Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. coli, rat liver and human erythrocytes. Nucleosides Nucleotides 14, 1861-1871 (1995).
6. Merta A, Votruba I, Jindrich J et al. Phosphorylation of 9-(2-phosphonomethoxyethyl)-adenine by AMP(dAMP) kinase from L1210. Biochem. Pharmacol. 44, 2067-2077 (1992).
7. Neyts J, Snoeck R, Balzarini J, De Clercq E. Particular characteristics of the antihuman cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (HPMPC) in vitro. Antiviral Res. 16, 41-52 (1991).
8. Ho H-T, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJM. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2(phosphonylmethoxy)propyl]-cytosine. Mol. Pharmacol. 41, 197-202 (1992).
9. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 63, 678-681 (2003).
10. Kern ER, Hartline C, Harden E et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46, 991-995 (2002).
11. Beadle JR, Hartline C, Aldern KA et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46, 2381-2386 (2002).
12. Kramata P, Votruba I, Otová B, Holý A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases α, λ and E. Mol. Pharmacol. 49, 1005-1011 (1996).
13. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 8, 1-23 (1997).
14. Birkus G, Hájek M, Kramata P, Votruba I, Holý A, Otová B. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases α, δ and E. Antimicrob. Agents Chemother. 46, 1610-1613 (2002).
15. Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41, 594-599 (1997).
16. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10, 523-531 (1998).
17. Murono S, Raab-Traub N, Pagano JS. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res. 61, 7875-7877 (2001).
18. Neyts J, Sadler R, De Clercq E, Raab-Traub N, Pagano JS. The antiviral agent cidofovir ([S]-1-[3-hydroxy-2-phosphonylmethoxypropyl]cytosine) has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res. 58, 384-388 (1998).
19. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol. Res. 12, 397-408 (2001).
20. Abdulkarim B, Sabri S, Deutsch E et al. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21, 2334-2346 (2002).
21. De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 3, 85-96 (1993).
22. Neyts J, De Clercq E. In vitro and in vivo inhibition of murine gamma herpes virus 68 replication by selected antiviral agents. Antimicrob. Agents Chemother. 42, 170-172 (1998).
23. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. J. Clin. Invest. 99, 2082-2086 (1997).
24. Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW. Characterization of wild type and cidofovir-resistant strains of camelpox, cowpox, monkeypox and vaccinia viruses. Antimicrob. Agents Chemother. 46, 1329-1335 (2002).
25. Nettleton PF, Gilray JA, Reid HW, Mercer AA. Parapoxviruses are strongly inhibited in vitro by cidofovir. Antiviral Res. 48, 205-208 (2000).
26. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 55, 1-13 (2002).
27. De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 23, 456-458 (2002).
28. De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev. Med. Virol. 11, 381-395 (2001).
29. Smee DF, Burger RA, Warren RP, Bailey KW, Sidwell RW. An immunosuppressed mouse model of lethal murine gammaherpesvirus 68 infection for studying potential treatment of Epstein-Barr virus infection in man. Antiviral Chem. Chemother. 8, 573-581 (1997).
30. Christensen ND, Pickel MD, Budgeon LR, Kreider JW. In vivo antipapillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Res. 48, 131-142 (2002).
31. Duan J, Paris W, De Marte J, Roopchand D, Fleet T-L, Cordingley MG. Topical effects of cidofovir on cutaneous rabbit warts: treatment regimen and inoculum dependence. Antiviral Res. 46, 135-144 (2000).
32. Neyts J, De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41, 242-246 (1993).
33. Smee DF, Bailey KW, Wong M-H, Sidwell RW. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 52, 55-62 (2001).
34. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181, 10-19 (2000).
35. Bray M, Martinez M, Kefauver D, West M, Roy R. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res. 54, 129-142 (2002).
36. Smee DF, Bailey KW, Wong M-H, Sidwell RW. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res. 47, 171-177 (2001).
37. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Inhibitory effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic-nude mice. Oncol. Res. 10, 533-539 (1998).
38. Liekens S, Andrei G, Vandeputte M, De Clercq E, Neyts J. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res. 58, 2562-2567 (1998).
39. Liekens S, Verbeken E, De Clercq E, Neyts J. Potent inhibition of hemangiosarcoma development in mice by cidofovir. Int. J. Cancer 92, 161-167 (2001)
40. Liekens S, Neyts J, De Clercq E, Verbeken E, Ribatti D, Presta M. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res. 61, 5057-5064 (2001).
41. Redondo P, Idoate M, Galofré JC, Solano T. Cidofovir inhibits growth of B16 melanoma cells in vivo. Br. J. Dermatol. 143, 741-748 (2002).
42. Cullen JM, Li DH, Brown C et al. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 45, 2740-2745 (2001).
43. Julander JG, Sidwell RW, Morrey JD. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 55, 27-40 (2002).
44. Delmas J, Schorr O, Jamard C et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob. Agents Chemother. 46, 425-433 (2002).
45. Tsai C-C, Follis KE, Sabo A et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270, 1197-1199 (1995).
46. Tsai C-C, Follis KE, Beck TW, Sabo A, Bischofberger N, Dailey PJ. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res. Hum. Retroviruses 13, 707-712 (1997).
47. Van Rompay KKA, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J. Infect. Dis. 184, 429-438 (2001).
48. Otten RA, Smith DK, Adams DR et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus Type 2). J. Virol. 74, 9771-9775 (2000).
49. Lalezari JP, Stagg RJ, Kuppermann BD et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 126, 257-263 (1997).
50. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann. Intern. Med. 126, 264-274 (1997).
51. Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci. 44, 97-106 (1998)
52. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. 56, 570-580 (1999).
53. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC peripheral cytomegalovirus retinitis trial. AIDS 14, 1571-1581 (2000).
54. Lalezari JP, Holland GN, Kramer F et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J. Acquir. Immune Defic. Syndrom. Human Retrovirol. 17, 339-344 (1998).
55. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the ganciclovir cidofovir cytomegalovirus retinitis trial. Am. J. Ophthalmol. 131, 457-467 (2001).
56. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36, 127-143 (1999).
57. Polis MA, Spooner KM, Baird BF et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother. 39, 882-886 (1995).
58. Platzbecker U, Bandt D, Thiede C et al. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 71, 880-885 (2001).
59. Ljungman P, Deliliers GL, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood 97, 388-392 (2001).
60. Kopp T, Geusau A, Rieger A, Stingl G. Successful treatment of an aciclovir-resistant herpes simplex Type 2 infection with cidofovir in an AIDS patient. Br. J. Dermatol. 147, 134-138 (2002).
61. Lalezari J, Schacker T, Feinberg J et al. A randomized, double-blinded, placebo-controlled trial of cidofovir gel for the treatment of acyclovir unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J. Infect. Dis. 176, 892-898 (1997).
62. Sacks SL., Shafran SD, Diaz-Mitoma F et al. A multicenter Phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob. Agents Chemother. 42, 2996-2999 (1998).
63. Blot N, Schneider P, Young P et al. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant. 26, 903-905 (2000).
64. Lalezari JP, Drew WL, Glutzer E et al. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)-propyl]cytosine (cidofovir): results of a Phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171, 788-796 (1995).
65. Hänel M, Fiedler F, Thorns C. AntiCD20 monoclonal antibody (rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 24, 491-494 (2001).
66. Meerbach A, Schacke M, Hyckel P. Kosmehl H, Wutzler P. Successful treatment of Epstein-Barr virus-associated tumors in a heart transplant patient with cidofovir. Case report. Abstracts 15th International Conference on Antiviral Research, Prague, Czech Republic, 17-21 March 2002. Antiviral Res. 53 (2002) (Abstract 62, no 91).
67. Mazzi R, Parisi SG, Sarmati L et al. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS 15, 2061-2063 (2001).
68. Fife K, Gill J, Bourboulia D, Gazzard B, Nelson M, Bower M. Cidofovir for the treatment of Kaposi's sarcoma in an HIV-negative homosexual man. Br. J. Dermatol. 141, 1136-1153 (1999).
69. Simonart T, Noel J-C, De Dobbeleer G et al. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: report of a case. J. Med. Virol. 55, 215-218 (1988).
70. Ribaud P, Scieux C, Freymuth F, Morinet F, Gluckman E. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin. Infect. Dis. 28, 690-691 (1999).
71. Legrand F, Berrebi D, Houhou N et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 27, 621-626 (2001).
72. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biology of Blood and Marrow. Tansplantation 7, 388-394 (2001)
73. De Luca A, Giancola ML, Ammassari A et al. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 14, F117-F121 (2000).
74. Brambella AM, Castagna A, Novati R et al. Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. J. Neurol. 246, 723-725 (1999).
75. De Luca A, Fantoni M, Tartaglione T, Antinori A. Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 52, 891-892 (1999).
76. Portilla J, Boix V, Román F, Reus S, Merino E. Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active antiretroviral therapy. J. Infect. 41, 182-184 (2000).
77. Razonable RR, Aksamit AJ, Wright AJ, Wilson JW. Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. Mayo Clin. Proc. 76, 1171-1175 (2001).
78. Zimmermann T, Stingele K, Hartmann M, Haas J, von Einsiedel R, Wildemann B. Succesful treatment of AIDS related PML with HAART and cidofovir. Eur. J. Med. Res. 6, 190-192 (2001).
79. Vats A, Shapiro R, Randhawa PS et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 75, 105-112 (2003).
80. Van Cutsem E, Snoeck R, Van Ranst M et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J. Med. Virol. 45, 230-235 (1995).
81. Snoeck R, Van Ranst M, Andrei G, Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N. Engl. J. Med. 333, 943-944 (1995).
82. Hengge UR, Tietze G. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm. Infect. 76, 143-152 (2000).
83. Schürmann D, Bergmann F, Temmesfield-Wollbrück B, Grobusch MP, Suttorp N. Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS 14, 1075-1076 (2000).
84. Matteelli A, Beltrame A, Graifemberghi S et al. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm. Dis. 28, 343-346 (2001).
85. Snoeck R, Bossens M, Parent D et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin. Infect. Dis. 33, 597-602 (2001).
86. Orlando G, Fasolo MM, Beretta R, Merli S, Cargnel A. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS 16, 447-450 (2002).
87. Snoeck R, Noël JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J. Med. Virol. 60, 205-209 (2000).
88. Koonsaeng S, Verschraegen C, Freedman R et al. Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. J. Med. Virol. 64, 195-198 (2001).
89. Snoeck R, Wellens W, Desloovere C et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine, HPMPC]. J. Med. Virol. 54, 219-225 (1998).
90. Bielamowicz S, Villagomez V, Stager SV, Wilson WR. Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope 112, 696-699 (2002).
91. Pransky SM, Magit AE, Kearns DB, Kang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch. Otolaryngol. Head Neck Surg. 125, 1143-1148 (1999).
92. Stragier I, Snoeck R, De Clercq E, Van den Oord JJ, Van Ranst M, De Greef H. Local treatment of HPV-induced skin lesions by cidofovir. J. Med. Virol. 67, 241-245 (2002).
93. Bienvenu B, Martinez F, Devergie A et al. Topical use of cidofovir induced acute renal failure. Transplantation 73, 661-662 (2002).
94. Meadows KP, Tyring SK, Pavia AT, Rallis TM. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch. Dermatol. 133, 987-990 (1997).
95. Ibarra V, Blanco JR, Oteo JA, Rosel L. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm. Venereol. 80, 315-316 (2000).
96. Geerinck K, Lukito G, Snoeck R et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 64, 543-549 (2001).
97. Kahn J, Lagakos S, Wulfsohn M et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy. J. Am. Med. Assoc. 282, 2305-2312 (1999).
98. Fisher EJ, Chaloner K, Cohn DL et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 15, 1695-1700 (2001).
99. Gilson RJ, Chopra KB, Newell AM et al. A placebo-controlled Phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J. Viral Hepatitis 6, 387-395 (1999).
100. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 358, 718-723 (2001).
101. Benhamou Y, Bochet M, Thibault V et al. Adefovir dipivoxil 10 mg suppresses HBV viral replication in HIV/HBV co-infected patients with lamivudine resistant HBV. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington USA, 24-28 February (2002).
102. Peters M, Hann HW, Martin P et al. Adefovir dipivoxil alone and in combination with lamivudine suppresses lam-resistant hepatitis B virus (HBV) replication: 16 week interim analysis. Abstracts 37th Annual Meeting of the European Association for the Study of Liver Diseases, Madrid, Spain, 17-21 April (2002).
103. Marcellin P, Chang T-T, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348, 808-816 (2003).
104. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32, 129-134 (2000).
105. Peters MG, Singer G, Howard T et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient. Transplantation 68, 1912-1914 (1999).
106. Walsh KM, Woodall T, Lamy P, Wight DGD, Bloor S, Alexander GJM. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 49, 436-440 (2001).
107. Mutimer D, Feraz-Neto BH, Harrison R et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 49, 860-863 (2001).
108. Mutimer D. Adefovir dipivoxil for the treatment of chronic hepatitis B. Abstracts Therapies for Viral Hepatitis, Boston, MA, USA, 29-31 October 2002. Antiviral Ther. 7, L84, no. 6 (2002).
109. Mutimer D, Hann H-WL, Buti M et al. Safety and efficacy of adding adefovir dipivoxil to lamivudine in decompensated patients with YMDD variant and a reduced response to lamivudine - one year results. Abstracts Therapies for Viral Hepatitis, Boston, MA, USA, 29-31 October 2002. Antiviral Ther. 7, L90, no. 16 (2002).
110. Bendele RA, Richardson FC. Adefovir nephrotoxicity and mitochondrial DNA depletion. Human Pathol. 33, 574 (2002).
111. Deeks SG, Barditch-Crovo P, Lietman PS et al. Safety, pharmacokinetics and antiretroviral activity of intravenous 9-[2-(R)-phosphonomethoxy)propyl]adenine, a novel antihuman immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42, 2380-2384 (1998).
112. Schooley RT, Ruane P, Myers RA et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16, 1257-1263 (2002).
113. Squires K, Pierone G, Berger D et al. Tenofovir DF: a 48-week final analysis from a Phase III randomized, double-blind placebo-controlled study in antiretroviral experienced patients. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA USA, 24-28 February (2002).
114. Staszewski S, Gallant J, Pozniak A et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. Abstracts XIV International AIDS Conference, Barcelona, Spain, 7-12 July (2002).
115. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 54, 37-45 (2002).
116. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46, 716-723 (2002).
117. Johnson AA, Ray AS, Hanes J et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276, 40847-40857 (2001).
118. Cooper D, Cheng A, Coakley D et al. AntiHBV activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV co-infected. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 24-28 February (2002).
119. Bochet M, Tubiana R, Benhamou Y et al. Tenofovir disoproxil fumarate suppresses lamivudine resistant HBV replication in patients co-infected with HIV/HBV. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 24-28 February (2002).
120. Cherrington JM. Human cytomegalovirus: resistance profile of cidofovir. Int. Antiviral News 5, 91-92 (1997).
121. Schürmann D, Bergmann F, Grobusch MP, Behnsch M, Liekfeld A. Lack of efficacy of cidofovir in treating AIDS-related cytomegalovirus retinitis after long-term treatment with ganciclovir. AIDS 12, 678-679 (1998).
122. Cihlar T, Fuller MD, Mulato AS, Cherrington JM. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248, 382-393 (1998).
123. Andrei G, Snoeck R, De Clercq E, Esnouf R, Fiten P, Opdenakker G. Resistance of herpes simplex virus Type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J. Gen. Virol. 81, 639-648 (2000).
124. Cherrington JM, Mulato AS, Fuller MD, Chen MS. Novel mutation (K70E) in human immunodeficiency virus Type 1 reverse transcriptase confers decreased susceptibility to 9-(-2-phosphonomethoxyethyl) adenine in vitro. Antimicrob. Agents Chemother. 40, 2212-2216 (1996).
125. Miller MD, Margot NA, Lamy PD et al. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J. Acquir. Immune Defic. Syndr. 27, 450-458 (2001).
126. Delaugerre C, Marcelin A-G, Thibault V et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coninfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob. Agents Chemother. 46, 1586-1588 (2002).
127. Chin R, Shaw T, Torresi J et al. In vitro susceptibilities of wild type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45, 2495-2501 (2001).
128. Tatti KM, Korba BE, Stang HL et al. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antiviral Res. 55, 141-150 (2002).
129. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348, 800-807 (2003).
130. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. Abstracts 37th Annual Meeting of the European Association for the Study of Liver Diseases, Madrid, Spain, 17-21 April (2002).
131. Srinivas RV, Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob. Agents Chemother. 42, 1484-1487 (1998).
132. Van Rompay KKA, Miller MD, Marthas ML, et al. Prophylactic and therapeutic benefits of short-term 9-(2-[R]-[phosphonomethoxy]propyl)-adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J. Virol. 74, 1767-1774 (2000).
133. Naeger LK, Margot NA, Miller MD. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus Type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46, 2179-2184 (2002).
134. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16, 1227-1235 (2002).
135. Margot NA, Johnson A, Cheng A, Coakley DF, Miller MD. Final 48-week genotypic and phenotypic analyses of study 907: tenofovir DF (TDF) added to stable background regimens. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington USA, 24-28 February (2002).
136. Harrigan PR, Miller MD, McKenna P, Brumme ZL, Larder BA. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus Type 1 isolates. Antimicrob. Agents Chemother. 46, 1067-1072 (2002).